Redefining Hematoma Expansion With the Inclusion of Intraventricular Hemorrhage Growth.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 23 2 2020
medline: 17 9 2020
entrez: 21 2 2020
Statut: ppublish

Résumé

Background and Purpose- Definitions of significant hematoma expansion traditionally focus on changes in intraparenchymal volume. The presence of intraventricular hemorrhage (IVH) is a predictor of poor outcome, but current definitions of hematoma expansion do not include IVH expansion. We evaluated whether including IVH expansion to current definitions of hematoma expansion improves the ability to predict 90-day outcome. Methods- Using data from the PREDICT-ICH study (Predicting Hematoma Growth and Outcome in Intracerebral Hemorrhage Using Contrast Bolus CT), we compared a standard definition of hematoma expansion (≥6 mL or ≥33%) to revised definitions that includes new IVH development or expansion (≥6 mL or ≥33% or any IVH; ≥6 mL or ≥33% or IVH expansion ≥1 mL). The primary outcome was poor clinical outcome (modified Rankin Scale score, 4-6) at 90 days. Diagnostic accuracy measures were calculated for each definition, and C statistics for each definition were compared using nonparametric methods. Results- Of the 256 patients eligible for primary analysis, 127 (49.6%) had a modified Rankin Scale score of 4 to 6. Sensitivity and specificity for the standard definition (n=80) were 45.7% (95% CI, 36.8-54.7) and 82.9% (95% CI, 75.3-88.9), respectively. The revised definition, ≥6 mL or ≥33% or any IVH (n=113), possessed a sensitivity of 63.8% (95% CI, 54.8-72.1) and specificity of 75.2% (95% CI, 66.8-82.4). Overall accuracy was significantly improved with the revised definition (

Identifiants

pubmed: 32078498
doi: 10.1161/STROKEAHA.119.027451
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1120-1127

Auteurs

Vignan Yogendrakumar (V)

From the Ottawa Stroke Program, Department of Medicine, Division of Neurology, (V.Y., D.D.), University of Ottawa, Canada.

Tim Ramsay (T)

Ottawa Methods Center (T.R., D.A.F.), University of Ottawa, Canada.
Ottawa Hospital Research Institute (T.R., D.A.F., D.D.), University of Ottawa, Canada.

Dean A Fergusson (DA)

Ottawa Methods Center (T.R., D.A.F.), University of Ottawa, Canada.
Ottawa Hospital Research Institute (T.R., D.A.F., D.D.), University of Ottawa, Canada.

Andrew M Demchuk (AM)

Calgary Stroke Program, Departments of Clinical Neurosciences (A.M.D., M.D.H.), Hotchkiss Brain Institute, University of Calgary, Canada.
Radiology (A.M.D., M.D.H.), Hotchkiss Brain Institute, University of Calgary, Canada.

Richard I Aviv (RI)

Department of Radiology (R.I.A.), University of Ottawa, Canada.

David Rodriguez-Luna (D)

Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (D.R.-L., C.A.M.).

Carlos A Molina (CA)

Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (D.R.-L., C.A.M.).

Yolanda Silva (Y)

Department of Neurology, Dr. Josep Trueta University Hospital, Institut d'Investigació Biomèdica Girona Foundation, Spain (Y.S.).

Imanuel Dzialowski (I)

Department of Neurology, Elblandklinikum Meissen Academic Teaching Hospital of the Technische University, Dresden, Germany (I.D.).

Adam Kobayashi (A)

Interventional Stroke and Cerebrovascular Treatment Center and 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.K.).
Department of Experimental and Clinical Pharmacology, Warsaw, Poland (A.K.).

Jean-Martin Boulanger (JM)

Department of Medicine, Charles LeMoyne Hospital, University of Sherbrooke, Longueuil, Canada (J.-M.B.).

Gord Gubitz (G)

Department of Neurology, Dalhousie University, Halifax, Canada (G.G.).

Padma Srivastava (P)

Department of Neurology, All India Institute of Medical Sciences, New Delhi (P.S., R.B.).

Jayanta Roy (J)

Apollo Gleneagles Hospitals, Kolkata (J.R.).

Carlos S Kase (CS)

Department of Neurology, Boston Medical Center, MA (C.S.K.).

Rohit Bhatia (R)

Department of Neurology, All India Institute of Medical Sciences, New Delhi (P.S., R.B.).

Michael D Hill (MD)

Calgary Stroke Program, Departments of Clinical Neurosciences (A.M.D., M.D.H.), Hotchkiss Brain Institute, University of Calgary, Canada.
Radiology (A.M.D., M.D.H.), Hotchkiss Brain Institute, University of Calgary, Canada.

Joshua N Goldstein (JN)

Department of Emergency Medicine, Massachusetts General Hospital, Boston (J.N.G.).

Dar Dowlatshahi (D)

From the Ottawa Stroke Program, Department of Medicine, Division of Neurology, (V.Y., D.D.), University of Ottawa, Canada.
Ottawa Hospital Research Institute (T.R., D.A.F., D.D.), University of Ottawa, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH